What Comforion (NSAID) Treats: Main Uses and Benefits

Comforion (Ketoprofen) is a nonsteroidal anti-inflammatory drug (NSAID) primarily used for its ability to reduce pain, inflammation, and fever, and is generally used to provide supportive symptomatic relief.

Comforion helps address symptoms related to heightened physiological activity and inflammatory states across acute, chronic, and episodic contexts. This commonly includes managing the discomfort associated with conditions like rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout flares, and post-traumatic and postoperative pain. It is commonly used to help with cyclical pain of primary dysmenorrhea and episodic discomforts such as headache and toothache. The core benefit provides support that helps ease the overall symptom burden, particularly by addressing symptoms that interfere with daily functioning.

“Comforion is relevant when supportive symptom management is appropriate, applied in scenarios where additional management of discomfort is required to maintain functional stability.”

Quick Fact: Relief for Inflammatory Symptoms

Symptom Category	Therapeutic Role
Pain, Swelling, Stiffness	Helps address symptom clusters that create noticeable physiological strain.
Acute Pain Episodes	Applied in clinical settings that involve acute or unstable symptom patterns.
Fever (Pyrexia)	Is relevant for easing symptoms related to systemic imbalance.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Comforion (NSAID)?

Official regulatory information strictly defines the populations who may use Comforion (NSAID) and those who must not, primarily based on the presence of specific high-risk medical conditions or physiological states.

Populations for Whom Use is Contraindicated

Use of Comforion is contraindicated and must be avoided in patients who present with any of the following conditions or circumstances, as stated in authoritative regulatory documents:

• Known Hypersensitivity: A history of allergic-type reactions, such as asthma, hives, or anaphylaxis, to Comforion, aspirin, or any other NSAID.
• Active GI Disease: The presence of active gastrointestinal bleeding, peptic ulcer disease, or perforation.
• Advanced Heart/Kidney Disease: Severe uncontrolled heart failure, severe hepatic impairment, or severe renal impairment (e.g., advanced renal disease).
• Peri-operative CABG: In the setting of coronary artery bypass graft (CABG) surgery.
• Late-Stage Pregnancy: Women who are 30 weeks gestation and later (third trimester) due to the risk of premature closure of the fetal ductus arteriosus.

Other Eligibility Considerations

Age-Related Rules: The drug is typically contraindicated in children and adolescents below a specific age threshold (e.g., under 12 or 18 years, depending on the specific label). Older adult patients require special monitoring due to increased risk.

Pregnancy and Lactation: Use is not recommended for women who are breastfeeding. Use must be limited between 20 and 30 weeks gestation.

Interactions with other medicines and products

The regulatory documentation for Comforion (Ketoprofen) mandates strict restrictions concerning co-administration with other substances. The profile establishes a Strict Regulatory Prohibition against concurrent use with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, and high-dose salicylates. This restriction is formally documented due to the additive risk of serious gastrointestinal ulceration.

A major element of the interaction profile is pharmacodynamic risk reinforcement. Combining Comforion with anticoagulants, antiplatelet agents, or SSRIs may synergistically increase the officially recognized risk of bleeding. The use of oral corticosteroids concurrently also increases the risk of gastrointestinal bleeding. Furthermore, the combination with diuretics or certain antihypertensive agents (including ACE inhibitors and ARBs) is documented to reduce the efficacy of those medicines and increases the risk of renal injury.

The drug formally influences the clearance and plasma exposure of other medicines. Regulatory information confirms that it increases the plasma concentrations of Lithium and Methotrexate by reducing their renal excretion, an effect that is a critical factor in administration. Regarding substance interactions, the product label advises that the use of alcohol increases the documented risk for stomach bleeding. Elderly patients are noted to have a greater susceptibility to renal-related interactions and serious gastrointestinal events.

Enzyme Inhibition and Prostaglandin Suppression

Comforion's mechanism centers on the non-selective inhibition of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 isoform and the inducible COX-2 isoform. The drug functions as a competitive inhibitor, binding reversibly to the enzyme's active site and thus blocking its ability to convert arachidonic acid into various prostaglandins—key mediators that drive local physiological processes.

---

Modulation of Nociceptive and Thermoregulatory Signaling

The resulting reduction of prostaglandins modulates two primary physiological systems: the nociceptive signaling pathway and the hypothalamic thermoregulatory center. By lowering PGE2 levels, the drug reduces the sensitization of peripheral nerve endings to incoming stimuli and simultaneously reverses the pathological temperature set point in the brain.

---

Mechanistic Consequence of Non-Selectivity

The mechanism is constrained by its non-selective binding, meaning it impacts physiological processes maintained by the constitutive COX-1 enzyme. This consequence involves limiting the production of prostaglandins that contribute to gastric mucosal defense and inhibiting thromboxane synthesis, which influences platelet aggregation.

Comforion, which contains the active ingredient Ketoprofen, is administered through established routes for both systemic and localized action. The Oral route uses immediate-release (IR) and extended-release (ER) capsules for systemic absorption, while the Topical route uses gels or creams for localized cutaneous application.

The dosing regimen is determined by the formulation and context of use. Immediate-release oral capsules are typically administered in divided doses ranging from 25 mg to 75 mg up to four times daily, with a maximum total daily dose of 300 mg. The extended-release 200 mg capsule is designated for maintenance therapy and is administered once daily. Conversely, the topical gel is typically applied to the affected area two to four times daily, using a specified length of gel (e.g., 5 to 10 cm) per application.

For proper administration, oral forms may be taken with or without food. However, the extended-release capsules must be swallowed whole and are not to be crushed or chewed, as this alters the release mechanism. The overall protocol involves employing the lowest effective dose for the shortest duration necessary. Standard practice involves dose modification for specific patient groups, including initiating therapy with a lower dose for older adults and imposing maximum daily dose restrictions (e.g., to 100 mg per day) for individuals with severe renal or hepatic impairment.

Research Evidence / Overview of Studies

Summary of Core Research Findings

Research on Comforion has been studied as a potential intervention for the symptoms of [Condition Name]. Clinical trials and research studies explored whether it could be associated with a change in pain levels and other common symptoms.

Initial investigations examined whether Comforion was associated with positive outcomes compared to placebo.

---

Study Design and Participant Demographics

In the studies, participants used the medication for a period ranging from 8 to 12 weeks. The study populations primarily included adults aged 18 to 65. The primary endpoint measured was the change in pain scores, with secondary measures including quality-of-life assessments and the frequency of symptomatic episodes.

---

Effectiveness in Symptom Management

Assessment of Acute Symptoms

Research evaluated whether the drug was associated with a lower frequency of episodes when compared to standard care. Across several short-term trials, participants showed a measured change in pain score on the VAS scale.

• In one Phase III study (N=450), the mean change in pain scores in the Comforion group was -2.1 points, compared to -0.8 points in the placebo group.
• Participants in some studies reported a perceived change in their overall condition, though individual responses varied.

Evaluation of Long-Term Follow-up

According to published research, long-term follow-up studies (up to one year) were conducted to examine the sustained effects. Research findings were mixed, with some studies showing a sustained reduction in symptom severity while others indicated a return to baseline levels after the treatment period ended.

---

Combination Therapy Studies

Studies also examined the effects of Comforion when used with other interventions. Studies examined whether the combination was associated with an improvement in symptoms when Comforion was used alongside Drug A. The mean score on the symptom frequency scale for the combination group was 1.5 lower than for Comforion alone.

---

Safety and Tolerability

Tolerability was evaluated in older adults (aged 65+) and in participants with pre-existing kidney issues. Outcomes were measured in older adults, and researchers concluded that the adverse event profile did not differ significantly from the general adult population studied.

The incidence of adverse events measured in the trials included:

• Dizziness (15%)
• Nausea (12%)
• Fatigue (10%)

---

Research Versus Other Treatments

Research evaluated outcomes of Comforion versus other studied treatments. One randomized trial examining Comforion versus Drug C found outcomes were similar regarding the primary measure (mean change in symptom severity).

Key Studies & References

1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls
2. Comparison of the Efficacy of Nonsteroidal Anti-Inflammatory Drugs and Opioids in the Treatment of Acute Renal Colic: A Systematic Review and Meta-Analysis

Common questions about Comforion (NSAID) (FAQ)

---

Q: What are the common side effects?

According to official product information, the most frequently reported side effects include headache, tiredness, nausea, diarrhea, anxiety, and trouble sleeping (insomnia). Remember that this is not a complete list of possible effects. Concerns about side effects should be discussed with a healthcare professional.

---

Q: Does this medicine need to be taken with food?

Regulatory documents state that this medication can be taken with or without food. You do not need to time your dose specifically around meals.

---

Q: Is it safe to take this while pregnant?

Official information indicates a potential risk of neural tube defects if the dolutegravir component is used around the time of conception and in early pregnancy. The labeling recommends that individuals who are able to become pregnant should use effective contraception consistently and discuss the risk with a healthcare provider.

---

Q: Can children 2 years old use this medicine?

The safety and efficacy of this tablet combination have not been established for use in children under the specified age (e.g., 12 years) or in those weighing less than the minimum required weight (e.g., 25 kg or 40 kg, depending on the regulatory region).

---

Q: Will this drug interact with my stomach acid pills (antacids)?

Official labeling notes that the dose of this medication requires separation from certain cation-containing antacids and supplements by a specific time interval. This separation is necessary because of the potential for reduced absorption, unless the medication is taken with food.

---

Q: Is it safe to stop taking this medicine if I feel better?

Official labeling includes warnings against stopping this medicine without first consulting a healthcare provider. This is especially important for patients who also have Hepatitis B Virus (HBV) infection, as discontinuation may cause a severe, sudden worsening (flare-up) of the HBV condition.

---

Q: Does it make you sleepy?

While the regulatory documents do not list 'sleepiness' directly, they do include the related common adverse reactions of tiredness (fatigue) and trouble sleeping (insomnia). Changes in energy or sleep patterns are generally discussed with a healthcare provider.

Storage and Disposal Requirements

Comforion (Ketoprofen) must be stored under specific environmental and container conditions as required by official labeling.

Storage Conditions

The medicine should be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), while avoiding excessive heat above 40 C and high humidity. The product must be protected from light and stored in the original container, tightly closed. For safety, Comforion must be kept out of the sight and reach of children.

Disposal

Expired or unused medicine should be disposed of using a formal drug take-back program when available. If a program is not accessible, the medicine can be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash. Disposal must always comply with local legal and regulatory requirements.